Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Community Bank & Trust Waco Texas

Community Bank & Trust Waco Texas lifted its position in Amgen Inc. (NASDAQ:AMGN) by 42.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,959 shares of the medical research company’s stock after acquiring an additional 2,968 shares during the quarter. Community Bank & Trust Waco Texas’ holdings in Amgen were worth $2,868,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after acquiring an additional 165,636 shares during the period. Northern Trust Corp increased its stake in shares of Amgen by 3.8% in the third quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after purchasing an additional 255,463 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Amgen by 1.1% during the third quarter. Bank of New York Mellon Corp now owns 5,437,182 shares of the medical research company’s stock valued at $1,461,297,000 after buying an additional 61,528 shares during the last quarter. Royal Bank of Canada lifted its holdings in Amgen by 11.4% in the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock worth $1,365,213,000 after purchasing an additional 518,689 shares during the period. Finally, Invesco Ltd. grew its position in Amgen by 15.9% in the 3rd quarter. Invesco Ltd. now owns 3,356,359 shares of the medical research company’s stock valued at $902,055,000 after buying an additional 459,340 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.1 %

NASDAQ:AMGN traded up $0.37 during mid-day trading on Wednesday, reaching $273.91. The stock had a trading volume of 509,800 shares, compared to its average volume of 2,815,341. The stock has a market cap of $146.92 billion, a P/E ratio of 21.72, a PEG ratio of 2.53 and a beta of 0.58. The business’s 50 day moving average is $276.11 and its 200 day moving average is $281.61. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter last year, the company posted $4.09 earnings per share. The company’s revenue for the quarter was up 19.8% compared to the same quarter last year. As a group, sell-side analysts predict that Amgen Inc. will post 19.45 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.29%. Amgen’s payout ratio is 72.06%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Truist Financial reaffirmed a “buy” rating and issued a $320.00 price target on shares of Amgen in a research note on Friday, April 12th. UBS Group cut their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. TD Cowen lowered their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $329.00 target price on shares of Amgen in a research note on Wednesday, April 3rd. Finally, SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.